The FDA has approved a labeling change of Bristol-Myers Squibb Co."s drug, Orencia. The label now says that studies show Orencia is effective for patients with rheumatoid arthritis for two years or less whereas its initial 2005 approval was for patients with moderate to severe rheumatoid arthritis not responding to treatment with other drugs, such as methotrexate.